CRP and major depressive disorder: CRP level as a secondary outcome measure is expected to be reduced by 50% between baseline and six weeks in the group treated with antidepressant and anti-inflammatory medication in the ‘Depression with inflammation’ stratum of the study and is not expected to change in the group treated with antidepressant only in the same stratum.